Bernstein Keeps Their Hold Rating on Tandem Diabetes Care (TNDM)
Bernstein analyst Lee Hambright maintained a Hold rating on Tandem Diabetes Care with a price target of $18.00. Hambright, who covers the Healthcare sector, has an average return of 8.5% and a 70.73% success rate. Tandem Diabetes Care also received a Hold rating from TR's Lila Implantra and a Buy rating from Barclays.
Bernstein analyst Lee Hambright maintained a Hold rating on Tandem Diabetes Care yesterday and set a price target of $18.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Hambright covers the Healthcare sector, focusing on stocks such as Intuitive Surgical, Insulet, and Medtronic. According to TipRanks, Hambright has an average return of 8.5% and a 70.73% success rate on recommended stocks.
In addition to Bernstein, Tandem Diabetes Care also received a Hold from TR | OpenAI – 4o’s Lila Implantra in a report issued on November 13. However, on November 19, Barclays maintained a Buy rating on Tandem Diabetes Care (NASDAQ: TNDM).
